Myricetin protects against lipopolysaccharide-induced disseminated intravascular coagulation by anti-inflammatory and anticoagulation effect
- Author:
Jing-Yi TAN
1
;
Xue-Qin CHEN
1
;
Bi-Jun KANG
1
;
Zi-Xi QIN
1
;
Jia-Hong CHEN
1
;
Ren-Dong HU
1
;
Liang-Cai WU
2
Author Information
- Publication Type:Journal Article
- Keywords: Anti-inflammatory; Disseminated intravascular coagulation; Lipopolysaccharide; Macrophages; Myricetin
- From: Asian Pacific Journal of Tropical Medicine 2018;11(3):255-259
- CountryChina
- Language:Chinese
- Abstract: Objective: To explore the therapeutic effect and mechanism of myricetin on disseminated intravascular coagulation (DIC). Methods: The DIC model was established by injection of 60 mg/kg LPS in KM mice, and the treatment groups were injected myricetin with different concentrations (25 or 50 mg/kg) 30 min before the model was established. Both coagulation indicators and organ function were tested, including PT, APTT, fibrinogen, AST, ALT, BUN and tissue section. In vitro, the inflammatory model of RAW 264.7 macrophage cells were established by 10 μg/mL LPS. The treatment group was treated with 50 μmol/mL myricetin for 30 min before LPS, and the expression of TNF-α and p-NF-κB was detected, further to explore the therapeutic mechanism. Results: LPS-induced DIC led to a reduction of fibrinogen and a rise of PT, APTT, AST, ALT, BUN levels, but the treatment of myricetin significantly inhibited these abnormalities. Histopathology analysis also revealed that myricetin remarkably protected the liver and renal damage. In vitro, the expression of TNF-α and p-NF-κB induced by LPS was repressed by myricetin. Conclusions: This study provides new insights into the protective effects of myricetin in LPS-induced DIC by anticoagulant and anti-inflammatory via suppressing the activation of p-NF-κB which decreased TNF-α level.
